Received Jan 30, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | Z005469 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
No additional AE; Pharmacist reported and AE for GARDASIL 9. Pharmacist reported that a patient had a 3-year gap between her first and second dose of GARDASIL 9. Patient received her first dose in December 2022, her second dose in October 2025, and her third dose on 0; This spontaneous report was received from a pharmacist and refers to a female patient of unknown age. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unspecified date in December 2022, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (dose, lot #, expiration date, route of administration and anatomical site of injection were not reported). On an unspecified date in October 2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (dose, lot #, expiration date, anatomical site of injection and route of administration were not reported). On 14-Jan-2026, the patient was vaccinated with the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), lot #Z005469, which has been verified to be a valid lot number, expiration date: 27-Feb-2026, administered at dose of 0.5 mL (dose, anatomical site of injection and route of administration were not reported). All vaccines were administered for prophylaxis. There was a 3-year gap between her first and second doses of the vaccine (Inappropriate schedule of product administration). No additional adverse event was reported (no adverse event).